Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients.

Zhang, Yang; Li, Zongjuan; Chen, Yixing; Yang, Ping; Hu, Yong; Zeng, Zhaochong; Du, Shisuo

Zhang, Yang; Li, Zongjuan; Chen, Yixing; Yang, Ping; Hu, Yong; Zeng, Zhaochong; Du, Shisuo.

Afiliação

Zhang Y; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China.
Li Z; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China.
Chen Y; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China.
Yang P; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China.
Hu Y; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China.
Zeng Z; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. Electronic address: zeng.zhaochong@zs-hospital.sh.cn.
Du S; Department of Radiation Oncology, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai 200032, China. Electronic address: du.shisuo@zs-hospital.sh.cn.

Transl Oncol ; 26: 101537, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36115075

Palavras-chave

Hepatocellular carcinoma; Immune regulation; Prognosis; Radiother apy; Soluble PD-L1

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google